Aptevo Historical Income Statement
| APVO Stock | USD 0.28 0.07 20.00% |
Historical analysis of Aptevo Therapeutics income statement accounts such as Interest Expense of 43.1 M, Selling General Administrative of 19.2 M or Total Revenue of 0.0 can show how well Aptevo Therapeutics performed in making a profits. Evaluating Aptevo Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Aptevo Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Aptevo Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aptevo Therapeutics is a good buy for the upcoming year.
Aptevo |
About Aptevo Income Statement Analysis
Aptevo Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Aptevo Therapeutics shareholders. The income statement also shows Aptevo investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Aptevo Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Aptevo Therapeutics. It is also known as Aptevo Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Aptevo Therapeutics income statement and represents the costs associated with goods and services Aptevo Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Aptevo Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Aptevo Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.At this time, Aptevo Therapeutics' Net Income Applicable To Common Shares is very stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 33.7M | 31.8M | 28.9M | 41.8M | Cost Of Revenue | 19.0M | 901K | 567K | 538.7K |
Aptevo Therapeutics income statement Correlations
Click cells to compare fundamentals
Aptevo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aptevo Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 2.2M | 1.4M | 1.1M | 901K | 567K | 538.7K | |
| Selling General Administrative | 16.2M | 14.0M | 14.7M | 13.9M | 11.8M | 19.2M | |
| Total Revenue | 23.1M | 32.4M | 4.3M | 12.3M | 3.1M | 0.0 | |
| Gross Profit | 12.5M | (13.5M) | 12.3M | 2.2M | (567K) | (538.7K) | |
| Other Operating Expenses | 41.0M | 31.8M | 33.7M | 31.8M | 28.9M | 47.1M | |
| Operating Income | (41.0M) | (27.5M) | (21.4M) | (28.6M) | (28.9M) | (30.3M) | |
| Ebit | (41.0M) | (27.5M) | (21.4M) | (28.6M) | (28.9M) | (30.3M) | |
| Research Development | 24.8M | 17.9M | 19.0M | 17.9M | 17.1M | 22.5M | |
| Ebitda | (38.7M) | (26.1M) | (20.3M) | (27.7M) | (28.3M) | (29.7M) | |
| Cost Of Revenue | 19.9M | 17.9M | 19.0M | 901K | 567K | 538.7K | |
| Total Operating Expenses | 41.0M | 31.8M | 33.7M | 31.8M | 28.9M | 41.8M | |
| Income Before Tax | (43.1M) | (30.9M) | (29.4M) | 7.0M | (18.7M) | (19.6M) | |
| Total Other Income Expense Net | (2.1M) | (3.4M) | (8.0M) | 35.7M | 10.2M | 10.7M | |
| Net Income | (40.4M) | (18.4M) | (27.3M) | 42.7M | (17.4M) | (18.3M) | |
| Income Tax Expense | (2.6M) | (12.5M) | (2.1M) | (35.7M) | (1.2M) | (1.3M) | |
| Net Income From Continuing Ops | (44.7M) | (30.9M) | (29.4M) | 7.0M | (17.6M) | (18.5M) | |
| Net Income Applicable To Common Shares | (40.4M) | (17.8M) | (28.5M) | 8.0M | 9.2M | 9.7M | |
| Reconciled Depreciation | 2.2M | 1.4M | 1.1M | 901K | 612K | 581.4K |
Pair Trading with Aptevo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Aptevo Stock
| 0.45 | DOMH | Dominari Holdings | PairCorr |
| 0.41 | A | Agilent Technologies Sell-off Trend | PairCorr |
| 0.38 | DNLI | Denali Therapeutics | PairCorr |
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.24) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (2.51) |
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.